Systematic review of association between metabolic syndrome and its components with neurocognitive impairment among HIV-infected population

SHI Rui-zi; HE Na

doi:10.16462/j.cnki.zhjbkz.2020.12.017

Volume 24 Issue 12

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2020 > 24(12): 1452-1458

SHI Rui-zi, HE Na. Systematic review of association between metabolic syndrome and its components with neurocognitive impairment among HIV-infected population[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(12): 1452-1458. doi: 10.16462/j.cnki.zhjbkz.2020.12.017

Citation:

SHI Rui-zi, HE Na. Systematic review of association between metabolic syndrome and its components with neurocognitive impairment among HIV-infected population[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(12): 1452-1458. doi: 10.16462/j.cnki.zhjbkz.2020.12.017

Citation:

PDF( 957 KB)

Systematic review of association between metabolic syndrome and its components with neurocognitive impairment among HIV-infected population

doi: 10.16462/j.cnki.zhjbkz.2020.12.017

SHI Rui-zi,
HE Na^,

Department of Epidemiology, School of Public Health, Fudan University; The Key Laboratory of Public Health Safety of Ministry of Education, Shanghai 200032, China

Funds:

China National Science and Technology Major Projects on Infectious Diseases 2018ZX10721102-004

Shanghai Municipal Health Commission GWTD2015S05

More Information

Corresponding author: HE Na, E-mail:nhe@fudan.edu.cn
Received Date: 2020-08-10
Rev Recd Date: 2020-10-24
Publish Date: 2020-12-10

Abstract

Abstract

To systematically review the literature about the association between metabolic syndrome (MS) and neurocognitive impairments (NCIs) among human immunodeficiency virus (HIV) infected patients. We systematically searched and reviewed related literature published on databases of Ovid Medline, Embase, CNKI, CQVIP and Wanfang Data from 1992 to 2019. Information excerpted from papers that met the inclusion and exclusion criteria were analyzed. A total of 22 articles were included, including 14 cross-sectional studies, seven cohort studies and one secondary analysis, which were mainly conducted in the United States. HIV-negative controls were included in ten studies. NCIs were assessed by using neuropsychological battery. Metabolic disturbance was prevalent and NCIs was also prevalent with obvious heterogeneity across different geographic areas. Summarized results suggested that MS was associated with increased risk of NCIs. In consideration of different scales applied in different studies for the neurocognitive assessment and related ability domains, the relationship between MS components and NCIs and/or ability domains was found to be complicated. Some of these studies revealed distinct differences in ability domains evaluation. Metabolic disturbance may increase risks of various aspects of NCIs in HIV patients. In view of the limited evidence, more research is needed in other regions and developing countries.
- Human immunodeficiency virus,
- Metabolic syndrome,
- Neurocognitive impairment,
- Systematic review

FullText(HTML)

References(37)

References

[1]	Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors[J]. AIDS, 1998, 12(7):F51-F58. DOI: 10.1097/00002030-199807000-00003.
[2]	Fernandes NC, Pulliam L. Inflammatory mechanisms and cascades contributing to neurocognitive impairment in HIV/AIDS[J]. Curr Top Behav Neurosci, 2019:1-27. DOI: 10.1007/7854-2019-100.
[3]	Valcour V, Shikuma CM, Shiramizu B, et al. Diabetes, insulin resistance, and dementia among HIV-1-infected patients[J]. J Acquir Immune Defic Syndr, 2005, 38(1):31-36. DOI: 10.1097/00126334-200501010-00006.
[4]	Valcour V, Sacktor N, Paul RH, et al. Insulin resistance is associated with cognition among HIV-1-infected patients: the Hawaii aging with HIV cohort[J]. J Acquir Immune Defic Syndr, 2006, 43(4):405-410. DOI: 10.1097/01.qai.0000243119.67529.f5.
[5]	Becker JT, Kingsley LA, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men[J]. Neurology, 2009, 73(16):1292-1299. DOI: 10.1212/WNL.0b013e3181bd10e7.
[6]	Wright EJ, Grund B, Robertson KR, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons[J]. Neurology, 2010, 75(10):864-873. DOI: 10.1212/WNL.0b013e3181f11bd8.
[7]	Crystal H, Weedon J, Holman S, et al. Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women[J]. J Neurovirol, 2011, 17(5): 469-476. DOI: 10.1007/s13365-011-0052-3.
[8]	Mccutchan JA, Marquiebeck J, Fitzsimons C, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder[J]. Neurology, 2012, 78(7):485-492. DOI: 10.1212/WNL.0b013e3182478d64.
[9]	Fabbiani M, Ciccarelli N, Tana M, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients[J]. HIV Med, 2013, 14(3):136-144. DOI: 10.1111/j.1468-1293.2012.01044.x.
[10]	Gustafson D, Mielke MM, Tien PC, et al. Anthropometric measures and cognition in middle-aged HIV-infected and uninfected women. The Women's Interagency HIV Study[J]. J Neurovirol, 2013, 19(6):574-585. DOI: 10.1007/s13365-013-0219-1.
[11]	Sattler FR, He J, Letendre S, et al. Abdominal obesity contributes to neurocognitive impairment in HIV-infected patients with increased inflammation and immune activation[J]. J Acquir Immune Defic Syndr, 2015, 68(3):281-288. DOI: 10.1097/QAI.0000000000000458.
[12]	Dufouil C, Richert L, Thiébaut R, et al. Diabetes and cognitive decline in a French cohort of patients infected with HIV-1[J]. Neurology, 2015, 85(12):1065-1073. DOI: 10.1212/WNL.0000000000001815.
[13]	Valcour V, Rubin LH, Tien P, et al. Human immunodeficiency virus (HIV) modulates the associations between insulin resistance and cognition in the current combination antiretroviral therapy (cART) era: a study of the Women's Interagency HIV Study (WIHS)[J]. J Neurovirol, 2015, 21(4):415-421. DOI: 10.1007/s13365-015-0330-6.
[14]	Mukerji SS, Locascio JJ, Misra V, et al. Lipid profiles and APOE4 allele impact midlife cognitive decline in HIV-infected men on antiretroviral therapy[J]. Clin Infect Dis, 2016, 63(8):1130-1139. DOI: 10.1093/cid/ciw495.
[15]	Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study[J]. Neurology, 2016, 86(4):334-340. DOI: 10.1212/WNL.0000000000002277.
[16]	Schouten J, Su T, Wit FW, et al. Determinants of reduced cognitive performance in HIV-1-infected middle-aged men on combination antiretroviral therapy[J]. AIDS, 2016, 30(7):1027-38. DOI: 10.1097/QAD.0000000000001017.
[17]	Okafor CN, Kelso NE, Bryant V, et al. Body mass index, inflammatory biomarkers and neurocognitive impairment in HIV-infected persons[J]. Psychol Health Med, 2017, 22(3):289-302. DOI: 10.1080/13548506.2016.1199887.
[18]	Yang J, Jacobson LP, Becker JT, et al. Impact of glycemic status on longitudinal cognitive performance in men with and without HIV infection[J]. AIDS, 2018, 32(13):1849-1860. DOI: 10.1097/QAD.0000000000001842.
[19]	Gascón MRP, Vidal JE, Mazzaro YM, et al. Neuropsychological assessment of 412 HIV-infected individuals in Sao Paulo, Brazil[J]. AIDS Patient Care STDS, 2018, 32(1):1-8. DOI: 10.1089/apc.2017.0202.
[20]	Jumare J, El-Kamary SS, Magder L, et al. Brief report: body mass index and cognitive function among HIV-1-infected individuals in China, India, and Nigeria[J]. J Acquir Immune Defic Syndr, 2019, 80(2):e30-e35. DOI: 10.1097/QAI.0000000000001906.
[21]	Khuder SS, Chen S, Letendre S, et al. Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients[J]. Neurology, 2019, 92(12):e1344-e1353. DOI: 10.1212/WNL.0000000000007125.
[22]	Yu B, Pasipanodya E, Montoya JL, et al. Metabolic syndrome and neurocognitive deficits in HIV infection[J]. J Acquir Immune Defic Syndr, 2019, 81(1):95-101. DOI: 10.1097/QAI.0000000000001964.
[23]	Pasipanodya EC, Montoya JL, Campbell LM, et al. Metabolic risk factors as differential predictors of profiles of neurocognitive impairment among older HIV+ and HIV- adults: an observational study[J]. Arch Clin Neuropsychol, 2019:acz040. DOI: 10.1093/arclin/acz040.
[24]	Rubin LH, Gustafson D, Hawkins KL, et al. Midlife adiposity predicts cognitive decline in the prospective Multicenter AIDS Cohort Study[J]. Neurology, 2009, 93(3):e261-e271. DOI: 10.1212/WNL.0000000000007779.
[25]	Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy[J]. AIDS, 1999, 13(10):1249-1253. DOI: 10.1097/00002030-199907090-00015.
[26]	Grant I, Franklin DR Jr, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline[J]. Neurology, 2014, 82(23):2055-2062. DOI: 10.1212/WNL.0000000000000492.
[27]	Frisardi V, Solfrizzi V, Seripa D, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease[J]. Ageing Res Rev, 2010, 9(4):399-417. DOI: 10.1016/j.arr.2010.04.007.
[28]	Crichton GE, Elias MF, Buckley JD, et al. Metabolic syndrome, cognitive performance, and dementia[J]. J Alzheimers Dis, 2012, 30(Suppl 2):S77-S87. DOI: 10.3233/JAD-2011-111022.
[29]	Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged[J]. Arch Neurol, 2009, 66(3):300-305. DOI: 10.1001/archneurol.2009.27.
[30]	杨馨, 杨峥嵘. HIV相关神经认知功能障碍的研究进展[J].国际流行病学传染病学杂志, 2016, 43(5):333-337. DOI: 10.3760/cma.j.issn.1673-4149.2016.05.011. Yang X, Yang ZR. Research progress on HIV-related neurocognitive dysfunction[J]. Inter J Epidemiol Infect Dis, 2016, 43(5):333-337. DOI: 10.3760/cma.j.issn.1673-4149.2016.05.011.
[31]	Ene L, Duiculescu D, Ruta SM. How much do antiretroviral drugs penetrate into the central nervous system?[J]. J Med Life, 2011, 4(4):432-439. http://europepmc.org/articles/PMC3227164/
[32]	Soulie C, Grudé M, Descamps D, et al. Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma[J]. J Antimicrob Chemother, 2017, 72(8):2351-2354. DOI: 10.1093/jac/dkx128.
[33]	Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications[J]. Brain Behav Immun, 2015, 45:1-12. DOI: 10.1016/j.bbi.2014.10.008.
[34]	De Benedetto I, Trunfio M, Guastamacchia G, et al. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs[J]. J Neurovirol, 2020, 26(5):642-651. DOI: 10.1007/s13365-020-00874-9.
[35]	Gonzalez H, Podany A, Al-Harthi L, et al. The far-reaching HAND of cART: cART effects on astrocytes[J]. J Neuroimmune Pharm, 2020. DOI: 10.1007/s11481-020-09907-w.
[36]	田金洲, 解恒革, 秦斌, 等.中国简短认知测试在痴呆诊断中的应用指南[J].中华医学杂志, 2016, 96(37):2945-2959. DOI: 10.3760/cma.j.issn.0376-2491.2016.37.001. Tian JZ, Xie HG, Qin B, et al. Guidelines for the application of the Chinese brief cognitive test in the diagnosis of dementia[J]. Natl Med J Chin, 2016, 96(37):2945-2959. DOI: 10.3760/cma.j.issn.0376-2491.2016.37.001.
[37]	Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort[J]. Neurology, 2004, 63(5):822-827. DOI: 10.1212/01.wnl.0000134665.58343.8d.